Literature DB >> 29357080

Lymphoma epidemiology in Korea and the real clinical field including the Consortium for Improving Survival of Lymphoma (CISL) trial.

Kwai Han Yoo1, Hyewon Lee2, Cheolwon Suh3.   

Abstract

Lymphomas are a heterogeneous group of disease entities with well-defined clinical, morphological, immunophenotypic, and cytogenetic characteristics. Moreover, regional and racial differences have been reported in their incidence and subtype compositions. Here, we reviewed the epidemiology of lymphomas and summarized the recent achievements in specific subtypes prevalent in Korean population, focusing on clinical studies conducted by the Consortium for Improving Survival of Lymphoma (CISL) of the Korean Society of Hematology Lymphoma Working Party (KSH-LWP).

Entities:  

Keywords:  Clinical trial; Epidemiology; Korea; Lymphoma

Mesh：

Year:  2018        PMID： 29357080     DOI： 10.1007/s12185-018-2403-9

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


  65 in total

1.  SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group.

Authors:  Yok-Lam Kwong; Won Seog Kim; Soon Thye Lim; Seok Jin Kim; Tiffany Tang; Eric Tse; Anskar Y H Leung; Chor-Sang Chim
Journal:  Blood       Date:  2012-08-23       Impact factor: 22.113

Review 2.  The 2016 revision of the World Health Organization classification of lymphoid neoplasms.

Authors:  Steven H Swerdlow; Elias Campo; Stefano A Pileri; Nancy Lee Harris; Harald Stein; Reiner Siebert; Ranjana Advani; Michele Ghielmini; Gilles A Salles; Andrew D Zelenetz; Elaine S Jaffe
Journal:  Blood       Date:  2016-03-15       Impact factor: 22.113

3.  Salvage chemotherapy of gemcitabine, dexamethasone, and cisplatin (GDP) for patients with relapsed or refractory peripheral T-cell lymphomas: a consortium for improving survival of lymphoma (CISL) trial.

Authors:  Byeong-Bae Park; Won Seog Kim; Cheolwon Suh; Dong-Yeop Shin; Jeong-A Kim; Hoon-Gu Kim; Won Sik Lee
Journal:  Ann Hematol       Date:  2015-08-08       Impact factor: 3.673

4.  Is there role of additional chemotherapy after definitive local treatment for stage I/II marginal zone lymphoma?: Consortium for Improving Survival of Lymphoma (CISL) study.

Authors:  Myeong Seok Koh; Won Seog Kim; Seok Jin Kim; Sung Yong Oh; Dok Hyun Yoon; Soon Il Lee; Junshik Hong; Moo Kon Song; Ho-Jin Shin; Jung Hye Kwon; Hyo Jung Kim; Yong Rok Do; Cheolwon Suh; Hyo Jin Kim
Journal:  Int J Hematol       Date:  2015-07-26       Impact factor: 2.490

5.  Phase II study of gemcitabine for treatment of patients with advanced stage marginal zone B-cell lymphoma: Consortium for Improving Survival of Lymphoma (CISL) trial.

Authors:  Sung Yong Oh; Won Seog Kim; Dae Ho Lee; Seok Jin Kim; Sung Hyun Kim; Baek Yeol Ryoo; Hye Jin Kang; Young Jin Choi; Joo Seop Chung; Hyo Jung Kim; Cheolwon Suh
Journal:  Invest New Drugs       Date:  2009-05-07       Impact factor: 3.850

6.  Survival in advanced diffuse large B-cell lymphoma in pre- and post-rituximab Eras in the United States.

Authors:  Binay Kumar Shah; Amir Bista; Bahman Shafii
Journal:  Anticancer Res       Date:  2014-09       Impact factor: 2.480

7.  Lymphopenia is an important prognostic factor in peripheral T-cell lymphoma (NOS) treated with anthracycline-containing chemotherapy.

Authors:  Yu Ri Kim; Jin Seok Kim; Soo Jeong Kim; Hyun Ae Jung; Seok Jin Kim; Won Seog Kim; Hye Won Lee; Hyeon Seok Eom; Seong Hyun Jeong; Joon Seong Park; June-Won Cheong; Yoo Hong Min
Journal:  J Hematol Oncol       Date:  2011-08-15       Impact factor: 17.388

8.  Prognostic factors in primary diffuse large B-cell lymphoma of adrenal gland treated with rituximab-CHOP chemotherapy from the Consortium for Improving Survival of Lymphoma (CISL).

Authors:  Yu Ri Kim; Jin Seok Kim; Yoo Hong Min; Dok Hyunyoon; Ho-Jin Shin; Yeung-Chul Mun; Yong Park; Young Rok Do; Seong Hyun Jeong; Joon Seong Park; Sung Yong Oh; Suee Lee; Eun Kyung Park; Joung-Soon Jang; Won-Sik Lee; Hwe-Won Lee; Hyeonseok Eom; Jae-Sook Ahn; Jae-Heon Jeong; Sun Kyung Baek; Seok Jin Kim; Won Seog Kim; Cheolwon Suh
Journal:  J Hematol Oncol       Date:  2012-08-13       Impact factor: 17.388

Review 9.  Review of the clinical research conducted by the Consortium for Improving Survival of Lymphoma of the Korean Society of Hematology Lymphoma Working Party.

Authors:  Cheolwon Suh; Won Seog Kim; Jin Seok Kim; Byeong-Bae Park
Journal:  Blood Res       Date:  2013-09-25

10.  Clinical features and treatment outcomes in patients with mantle cell lymphoma in Korea: Study by the Consortium for Improving Survival of Lymphoma.

Authors:  Byung Woog Kang; Sang Kyun Sohn; Joon Ho Moon; Yee Soo Chae; Jong Gwang Kim; Soo Jung Lee; Won Seog Kim; Je-Jung Lee; Se Ryeon Lee; Keon Uk Park; Ho Sup Lee; Won Sik Lee; Jong-Ho Won; Moo-Rim Park; Jae-Yong Kwak; Min Kyoung Kim; Hyo Jung Kim; Sung Yong Oh; Hye Jin Kang; Cheolwon Suh
Journal:  Blood Res       Date:  2014-03-24
View more
  9 in total

1.  Validation of risk prediction tools in elderly patients who initiate dialysis.

Authors:  Dohui Hwang; Eunbin Lee; Samel Park; Byung Chul Yoo; Suyeon Park; Kyoung Jin Choi; Songhee Oh; Mi Jung Kim; Hyoungnae Kim; Jin Seok Jeon; Hyunjin Noh; Dong Cheol Han; Soon Hyo Kwon
Journal:  Int Urol Nephrol       Date:  2019-05-27       Impact factor: 2.370

2.  Lymphoma cell-derived extracellular vesicles inhibit autophagy and apoptosis to promote lymphoma cell growth via the microRNA-106a/Beclin1 axis.

Authors:  Junling Tang; Peng Hu; Shixia Zhou; Tiejun Zhou; Xiaoming Li; Li Zhang
Journal:  Cell Cycle       Date:  2022-03-13       Impact factor: 5.173

Review 3.  Treatment of indolent lymphoma.

Authors:  Seong Hyun Jeong
Journal:  Blood Res       Date:  2022-04-30

Review 4.  Extranodal NK/T cell lymphoma.

Authors:  Seong Hyun Jeong
Journal:  Blood Res       Date:  2020-07-31

5.  Increased risk of lymphoid malignancy in patients with herpes zoster: a longitudinal follow-up study using a national cohort.

Authors:  Hyo Geun Choi; James L Zehnder; Young Kyung Lee; Hyun Lim; Miyoung Kim
Journal:  BMC Cancer       Date:  2019-11-27       Impact factor: 4.430

6.  Real world data on follicular lymphoma patients treated by rituximab-containing immunochemotherapy and rituximab maintenance.

Authors:  Hee Kyung Kim; Wonseok Kang; Dong Hyun Sinn; Joon Hyeok Lee; Won Seog Kim; Seok Jin Kim
Journal:  Korean J Intern Med       Date:  2019-04-04       Impact factor: 2.884

7.  Prognostic significance of interim PET/CT response for the treatment of advanced-stage marginal zone lymphoma in the post-rituximab era.

Authors:  Ho-Young Yhim; Deok-Hwan Yang; Ga-Young Song; Sang Eun Yoon; Seok Jin Kim; Jin Seok Kim; Youngil Koh; Joon-Ho Moon; Sung Yong Oh; Ho Sup Lee; Ho-Jin Shin; Young Rok Do; Won Sik Lee; Dae Sik Kim; Yong Park
Journal:  Sci Rep       Date:  2020-07-15       Impact factor: 4.379

8.  Diagnostic Accuracy and Prognostic Relevance of Immunoglobulin Heavy Chain Rearrangement and 18F-FDG-PET/CT Compared With Unilateral Bone Marrow Trephination for Detecting Bone Marrow Involvement in Patients With Diffuse Large B-Cell Lymphoma.

Authors:  Mihee Kim; Seo-Yeon Ahn; Jae-Sook Ahn; Ga-Young Song; Sung-Hoon Jung; Je-Jung Lee; Hyeoung-Joon Kim; Jun Hyung Lee; Myung-Geun Shin; Sang Yun Song; Deok-Hwan Yang
Journal:  J Korean Med Sci       Date:  2022-01-03       Impact factor: 2.153

9.  The incidence of uveitis after systemic lymphoma in Taiwan: An 18-year nationwide population-based cohort study.

Authors:  Yu-Te Huang; Chun-Ju Lin; Pei-Lun Liao; Min-Yen Hsu; Cheng-Hsien Chang; Peng-Tai Tien; Chun-Ting Lai; Ning-Yi Hsia; Henry Bair; Huan-Sheng Chen; Chun-Chi Chiang; Yi-Yu Tsai
Journal:  Medicine (Baltimore)       Date:  2022-02-25       Impact factor: 1.817
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.